ClinicalTrials.gg
RecruitingNCT06417086Updated May 21, 2025

Clinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers

An interventional study of Acupuncture and Sham Acupuncture in Alzheimer Disease and Cognitive Impairment, sponsored by ZhanYJ. Recruiting at 1 site in China. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by ZhanYJ · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Planned enrollment
66th of 176
176 · median 100
Started
2024
with 40 others
No phase
78 of 260
47 open now
Primary completion
2026-11
later than 54 of 161 live
Registered
141st of 260
by date

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 66th largest by planned enrollment of the 176 interventional ones that give a count, is one of 41 that started in 2024, is one of 78 with no phase, reaches primary completion later than 54 of the 161 other live ones, and was the 141st registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if acupuncture works to treat mild-to-moderate Alzheimer's disease, as well as the difference of its effect in APOE e4 carriers and non-carriers. It will also learn about the safety of acupuncture.

Researchers will compare acupuncture to a placebo (sham acupuncture) to see if acupuncture works to relieve the cognitive impairment and improve the ability of daily living and the quality of life. In addition, the plasma and neuroimaging biomarkers will be included as objective indexes.

Participants will:

Experience acupuncture or sham acupuncture 3 times per week for 12 weeks, and receive a 52-week follow-up.

Visit the clinic at Week 12, Week 38 and Week 64 for checkups and tests.

Read the detailed description

This is a two-centre randomized controlled trial. A total of 176 participants with mild-to-moderate Alzheimer's disease, 88 APOE e4 carriers and 88 non-carriers, will be randomly assigned to either an acupuncture combined with donepezil group or a sham acupuncture combined with donepezil group with a ratio of 1:1. The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39. There will be 12 weeks of 3-session treatment for each participant, and a 52-week follow-up in total. The primary outcome is the change and effective rate from baseline in the ADAS-cog score measured at Week 12.

03

Conditions studied

  • Alzheimer Disease
  • Cognitive Impairment
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 50-85 years
  • Diagnosed by the criteria of Neurological Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA)
  • Cognitive impairment based on the scores of the Chinese version of the (MMSE) (patients with mild to moderate Alzheimers disease, 11≤primary school degree≤22, 11≤junior high school degree or above≤26
  • Magnetic resonance imaging (MRI) confirmation of atrophy of the hippocampus or the medial temporal lobe volume, MRI manifestation of high possibility of Alzheimer Disease
  • The Medial Temporal Lobe Atrophy Rating Scale (MTA-scale) score (≥2 for those under 75 years, and ≥3 for those over 75 years)
  • Voluntarily joining this study with informed consents

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment caused by other factors (e.g. vascular dementia, dementia with Lewy bodies, frontotemporal dementia, hormone or metabolic abnormalities, hypothyroidism, folic acid or vitamin B12 deficiency, delirium or other mental and emotional disorders (such as schizophrenia and depression))
  • A serious heart condition, hepatic disease, renal system disease, hematopoietic system disease, or whole-body malnutrition
  • Aphasia, disturbance of consciousness, or failure to cooperate with the related examinations due to physical disability
  • to undergoing an MRI scan such as claustrophobia or pacemaker implantation.
  • Anticoagulant treatments such as warfarin or heparin
  • Use of pacemakers or receiving acupuncture in the past 2 weeks
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    Acupuncture Treatment

    Participants in this group will receive acupuncture treatment in combination with donepezil for 12 weeks.

    Other: Acupuncture · Drug: Donepezil

  • Active comparator
    Sham Acupuncture Treatment

    Participants in this group will receive sham acupuncture treatment in combination with donepezil for 12 weeks.

    Other: Sham Acupuncture · Drug: Donepezil

Interventions

  • OtherAcupuncture

    The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.

  • OtherSham Acupuncture

    The Streitberger placebo needle will be used to simulate an acupuncture procedure without penetrating the skin. The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.

  • Donepezil 5 mg will be given once daily before bed-time for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Alzheimer's Disease Assessment Scale-cognition (ADAS-cog)

    The maximum score of the ADAS-cog is 70 including 12 items. The questions in this scale contain word recall task, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition task, remembering test directions, spoken language, word-finding difficulty, comprehension and attention. In general, a normal score for someone who does not have AD or another type of dementia is 5. The higher scores indicate higher degree of cognitive dysfunction.

    Time frame: Change from baseline to Week 12

Secondary outcomes

  1. Alzheimer's Disease Assessment Scale-cognition (ADAS-cog)

    The maximum score of the ADAS-cog is 70 including 12 items. The questions in this scale contain word recall task, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition task, remembering test directions, spoken language, word-finding difficulty, comprehension and attention. In general, a normal score for someone who does not have AD or another type of dementia is 5. The higher scores indicate higher degree of cognitive dysfunction.

    Time frame: Change from baseline to Week 38 (Follow-up 1) and Week 64 (Follow-up 2)

  2. Alzheimer's Disease Cooperative Study-Activity of Daily Living (ADCS-ADL)

    The maximum of the ADCS-ADL score is 54 containing 19 domains about assessment of basic and operational ability of daily living. The higher scores indicate higher ability of daily living.

    Time frame: Change from baseline to Week 12, Week 38 (Follow-up 1) and Week 64 (Follow-up 2)

  3. Quality of Life-Alzheimer's Disease(QOL-AD)

    The QOL-AD score includes 13 items about physical health, mental health, social and financial assessment, and quality of life. The total score ranges from 13 to 52. The higher scores indicate higher quality of life.

    Time frame: Change from baseline to Week 12, Week 38 (Follow-up 1) and Week 64 (Follow-up 2)

Other outcomes

  1. Phosphorylated tau at threonine 181 (p-tau181)

    Plasma p-tau181measured by Single Molecule Array (Simoa) as the plasma biomarker.

    Time frame: Change from baseline to Week 12 and Week 64 (Follow-up 2)

  2. Cerebral Blood Flow (CBF)

    CBF acquired by arterial spin labeling (ASL) magnetic resonance imaging (MRI) technique measures the blood flow condition of the whole brain.

    Time frame: Change from baseline to Week 12 and Week 64 (Follow-up 2)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Nov 2026, 29 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 29 months is close to that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2024
First posted
May 16, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06417086
Lead sponsor
ZhanYJ
Collaborators
Shanghai Minimally Invasive Surgery Center
Responsible party
ZhanYJ (Shanghai University of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine) — Sponsor-investigator
First posted
May 16, 2024
Start date
Jun 1, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
May 21, 2025

Study contacts

Yijun Zhan
Contact
jenniferzhan_lhzj@163.com
+8618917699167
Yijun Zhan
study chair · Shanghai University of Traditional Chinese Medicine
Houguang Zhou
study director · Huashan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion